Enzymatica’s ColdZyme Secures CE Mark

Enzymatica’s ColdZyme, an oral cold and flu treatment, has been given the CE mark by a European-recognised notified agency for medical devices, Eurofins.  

ColdZyme is a nasal spray designed to form a physical barrier that covers the throat to manage cold and flu symptoms and safeguard against viruses responsible for upper respiratory tract infections.  

The updated medical device regulations have objectives to reduce risk to patients by implementing more rigorous evaluation techniques and market oversight.  

“This is an important milestone in the history of Enzymatica, as the MDR certification validates our scientific data and creates great commercial opportunities for us.”  

“In addition, it increases consumer confidence in ColdZyme as well as opens up new markets. The certification is highly anticipated by our partners since it ensures long-term security, which will contribute to Enzymatica’s growth.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.